PMID- 36221336
OWN - NLM
STAT- MEDLINE
DCOM- 20221013
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 40
DP  - 2022 Oct 7
TI  - Astrocytoma with myelin oligodendrocyte glycoprotein antibody associated 
      encephalomyelitis: A case report.
PG  - e31003
LID - 10.1097/MD.0000000000031003 [doi]
LID - e31003
AB  - BACKGROUND: Demyelination is similar with malignancy in clinical symptoms. 
      Magnetic resonance imaging (MRI) is an important auxiliary examination in the 
      diagnosis of demyelinating diseases and malignancy. Since MRI and symptoms can be 
      difficult to distinguish demyelination from malignancy, other auxiliary 
      examinations, such as demyelinating disease-specific antibodies, play an 
      important role in distinguishing them. Previous studies have reported 
      demyelinating disease-specific antibodies in patients with malignancy. What's 
      more, it is more difficult to confirm the diagnosis when the malignant tumor 
      co-occurs with demyelinating diseases, which has never been reported in previous 
      studies. We report the diagnosis of myelin oligodendrocyte glycoprotein antibody 
      associated encephalomyelitis (MOG-EM) in a patient who had astrocytoma for 
      several years. CASE PRESENTATION: Patient's concerns and diagnoses: our case 
      report records a 49-year-old woman with astrocytoma for more than 4 years, who 
      recently developed the symptoms of MOG-EM, including dizziness, vomiting, and 
      vision loss. This astrocytoma patient was diagnosed with MOG-EM according to 
      comprehensive evidence, including MRI, visual evoked potential (VEP), serum 
      myelin oligodendrocyte glycoprotein antibody (MOG-IgG), and therapeutic effect. 
      Interventions and outcomes: this patient was diagnosed with astrocytoma by 
      surgical biopsy 4 years earlier. This patient has been treated with tumor 
      resection, postoperative radiation treatment and chemotherapy. After treatment, 
      the patient was left with right limb weakness while other symptoms were improved. 
      Recently, the intravenous steroid agent was used to treat this patient after 
      being diagnosed with MOG-EM. Dizziness, vomiting, and vision loss have gone into 
      remission. This patient did not relapse in 7 months after discharge. This patient 
      is still being followed up at the outpatient clinic. And the patient will next be 
      treated with azathioprine. CONCLUSIONS: In previous studies, polyclonal antibody 
      has been found in cancer patients, such as aquaporin-4 and MOG-IgG in astrocytoma 
      patients. But the case of our study finds that astrocytoma can coexist with 
      MOG-EM. Therefore, MOG-EM should not be excluded easily in astrocytoma patients 
      when the relative antibody of encephalomyelitis is positive. What's more, it 
      reminds us that the pathogenesis of MOG-EM might be related to astrocytoma.
CI  - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Zhong, Guanghong
AU  - Zhong G
AD  - Heyuan People's Hospital, Heyuan, Guangdong, China.
FAU - Zhang, Jia
AU  - Zhang J
FAU - Liu, Xi
AU  - Liu X
AUID- ORCID: 0000-0002-1484-0233
FAU - Yang, Shaoming
AU  - Yang S
FAU - Gu, Hongli
AU  - Gu H
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Aquaporin 4)
RN  - 0 (Autoantibodies)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Myelin-Oligodendrocyte Glycoprotein)
RN  - 0 (Steroids)
RN  - MRK240IY2L (Azathioprine)
SB  - IM
MH  - Aquaporin 4
MH  - *Astrocytoma/diagnosis/therapy
MH  - Autoantibodies
MH  - Azathioprine
MH  - *Demyelinating Diseases
MH  - Dizziness
MH  - *Encephalomyelitis
MH  - Evoked Potentials, Visual
MH  - Humans
MH  - Immunoglobulin G
MH  - Myelin-Oligodendrocyte Glycoprotein
MH  - Neoplasm Recurrence, Local
MH  - Steroids
MH  - Vomiting
PMC - PMC9542675
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2022/10/13 06:00
MHDA- 2022/10/14 06:00
PMCR- 2022/10/07
CRDT- 2022/10/12 01:52
PHST- 2022/10/12 01:52 [entrez]
PHST- 2022/10/13 06:00 [pubmed]
PHST- 2022/10/14 06:00 [medline]
PHST- 2022/10/07 00:00 [pmc-release]
AID - 00005792-202210070-00013 [pii]
AID - 10.1097/MD.0000000000031003 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Oct 7;101(40):e31003. doi: 
      10.1097/MD.0000000000031003.